ID   NAGPA_HUMAN             Reviewed;         515 AA.
AC   Q9UK23; B2RAS1; Q96EJ8;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   10-MAY-2017, entry version 138.
DE   RecName: Full=N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase;
DE            EC=3.1.4.45;
DE   AltName: Full=Mannose 6-phosphate-uncovering enzyme;
DE   AltName: Full=Phosphodiester alpha-GlcNAcase;
DE   Flags: Precursor;
GN   Name=NAGPA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT ILE-465.
RX   PubMed=10551838; DOI=10.1074/jbc.274.46.32778;
RA   Kornfeld R.H., Bao M., Brewer K., Noll C., Canfield W.M.;
RT   "Molecular cloning and functional expression of two splice forms of
RT   human N-acetylglucosamine-1-phosphodiester alpha-N-
RT   acetylglucosaminidase.";
RL   J. Biol. Chem. 274:32778-32785(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 26-36, SIGNAL SEQUENCE CLEAVAGE SITE, PROTEOLYTIC
RP   PROCESSING, AND SUBCELLULAR LOCATION.
RX   PubMed=12058031; DOI=10.1074/jbc.M202369200;
RA   Do H., Lee W.S., Ghosh P., Hollowell T., Canfield W., Kornfeld S.;
RT   "Human mannose 6-phosphate-uncovering enzyme is synthesized as a
RT   proenzyme that is activated by the endoprotease furin.";
RL   J. Biol. Chem. 277:29737-29744(2002).
RN   [7]
RP   POSSIBLE INVOLVEMENT IN PERSISTENT STUTTERING, AND VARIANTS GLN-84 AND
RP   CYS-328.
RX   PubMed=20147709; DOI=10.1056/NEJMoa0902630;
RA   Kang C., Riazuddin S., Mundorff J., Krasnewich D., Friedman P.,
RA   Mullikin J.C., Drayna D.;
RT   "Mutations in the lysosomal enzyme-targeting pathway and persistent
RT   stuttering.";
RL   N. Engl. J. Med. 362:677-685(2010).
RN   [8]
RP   MUTAGENESIS OF CYS-51; CYS-115; CYS-132; ASN-137; CYS-221; GLN-225;
RP   THR-227; ARG-247; ASN-284; ASP-286; GLY-287; GLY-288; GLY-289;
RP   SER-290; THR-320 AND VAL-322, 3D-STRUCTURE MODELING, DISULFIDE BONDS,
RP   AND FUNCTION.
RX   PubMed=23572527; DOI=10.1074/jbc.M112.434977;
RA   Das D., Lee W.S., Grant J.C., Chiu H.J., Farr C.L., Vance J.,
RA   Klock H.E., Knuth M.W., Miller M.D., Elsliger M.A., Deacon A.M.,
RA   Godzik A., Lesley S.A., Kornfeld S., Wilson I.A.;
RT   "Structure and function of the DUF2233 domain in bacteria and in the
RT   human mannose 6-phosphate uncovering enzyme.";
RL   J. Biol. Chem. 288:16789-16799(2013).
RN   [9]
RP   INTERACTION WITH AP4M1, AND MUTAGENESIS OF TYR-486; TYR-488 AND
RP   LEU-491.
RX   PubMed=26544806; DOI=10.1016/j.ajhg.2015.10.007;
RA   Raza M.H., Mattera R., Morell R., Sainz E., Rahn R., Gutierrez J.,
RA   Paris E., Root J., Solomon B., Brewer C., Basra M.A., Khan S.,
RA   Riazuddin S., Braun A., Bonifacino J.S., Drayna D.;
RT   "Association between rare variants in AP4E1, a component of
RT   intracellular trafficking, and persistent stuttering.";
RL   Am. J. Hum. Genet. 97:715-725(2015).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Catalyzes the second step in the formation of the
CC       mannose 6-phosphate targeting signal on lysosomal enzyme
CC       oligosaccharides by removing GlcNAc residues from GlcNAc-alpha-P-
CC       mannose moieties, which are formed in the first step. Also
CC       hydrolyzes UDP-GlcNAc, a sugar donor for Golgi N-
CC       acetylglucosaminyltransferases. {ECO:0000269|PubMed:23572527}.
CC   -!- CATALYTIC ACTIVITY: Glycoprotein N-acetyl-D-glucosaminyl-phospho-
CC       D-mannose + H(2)O = N-acetyl-D-glucosamine + glycoprotein phospho-
CC       D-mannose.
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC   -!- SUBUNIT: Homotetramer arranged as two disulfide-linked homodimers.
CC       Interacts with AP4M1. {ECO:0000250|UniProtKB:P68827,
CC       ECO:0000269|PubMed:26544806}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, Golgi stack membrane
CC       {ECO:0000269|PubMed:12058031}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:12058031}. Golgi apparatus, trans-Golgi
CC       network {ECO:0000269|PubMed:12058031}. Note=Cis/medial Golgi.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UK23-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UK23-2; Sequence=VSP_012269;
CC       Name=3;
CC         IsoId=Q9UK23-3; Sequence=VSP_012267, VSP_012268;
CC   -!- TISSUE SPECIFICITY: Isoform 2 may be brain-specific.
CC   -!- DOMAIN: The tyrosine-based internalization signal may be essential
CC       for its retrieval from the plasma membrane to the TGN.
CC   -!- DOMAIN: The C-terminal NPFKD sequence is an attractive candidate
CC       for either an endocytosis signal acting at the plasma membrane or
CC       a retrieval signal acting at the TGN to return the enzyme to the
CC       cis/medial-Golgi.
CC   -!- PTM: The precursor is cleaved and activated in the trans-Golgi
CC       network by a furin endopeptidase. {ECO:0000269|PubMed:12058031}.
CC   -!- DISEASE: Note=Defects in NAGPA have been suggested to play a role
CC       in susceptibility to persistent stuttering. Stuttering is a common
CC       speech disorder characterized by repetitions, prolongations, and
CC       interruptions in the flow of speech.
CC       {ECO:0000269|PubMed:20147709}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF187072; AAF08273.1; -; mRNA.
DR   EMBL; AK127952; BAG54605.1; -; mRNA.
DR   EMBL; AK314320; BAG36968.1; -; mRNA.
DR   EMBL; AC026458; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471112; EAW85245.1; -; Genomic_DNA.
DR   EMBL; BC012194; AAH12194.1; -; mRNA.
DR   CCDS; CCDS10527.1; -. [Q9UK23-1]
DR   RefSeq; NP_057340.2; NM_016256.3. [Q9UK23-1]
DR   UniGene; Hs.21334; -.
DR   ProteinModelPortal; Q9UK23; -.
DR   SMR; Q9UK23; -.
DR   BioGrid; 119351; 13.
DR   IntAct; Q9UK23; 2.
DR   STRING; 9606.ENSP00000310998; -.
DR   ChEMBL; CHEMBL5920; -.
DR   DrugBank; DB00141; N-Acetyl-D-glucosamine.
DR   iPTMnet; Q9UK23; -.
DR   PhosphoSitePlus; Q9UK23; -.
DR   BioMuta; NAGPA; -.
DR   DMDM; 296439239; -.
DR   EPD; Q9UK23; -.
DR   PaxDb; Q9UK23; -.
DR   PeptideAtlas; Q9UK23; -.
DR   PRIDE; Q9UK23; -.
DR   Ensembl; ENST00000312251; ENSP00000310998; ENSG00000103174. [Q9UK23-1]
DR   Ensembl; ENST00000381955; ENSP00000371381; ENSG00000103174. [Q9UK23-2]
DR   Ensembl; ENST00000562746; ENSP00000455900; ENSG00000103174. [Q9UK23-3]
DR   GeneID; 51172; -.
DR   KEGG; hsa:51172; -.
DR   UCSC; uc002cyg.4; human. [Q9UK23-1]
DR   CTD; 51172; -.
DR   DisGeNET; 51172; -.
DR   GeneCards; NAGPA; -.
DR   H-InvDB; HIX0013112; -.
DR   HGNC; HGNC:17378; NAGPA.
DR   HPA; HPA064055; -.
DR   MalaCards; NAGPA; -.
DR   MIM; 607985; gene.
DR   neXtProt; NX_Q9UK23; -.
DR   OpenTargets; ENSG00000103174; -.
DR   PharmGKB; PA134940049; -.
DR   eggNOG; ENOG410IF19; Eukaryota.
DR   eggNOG; ENOG410ZT6Y; LUCA.
DR   GeneTree; ENSGT00730000111213; -.
DR   HOGENOM; HOG000059612; -.
DR   HOVERGEN; HBG052571; -.
DR   InParanoid; Q9UK23; -.
DR   KO; K01125; -.
DR   OMA; ELSFFTR; -.
DR   OrthoDB; EOG091G05YS; -.
DR   PhylomeDB; Q9UK23; -.
DR   TreeFam; TF331920; -.
DR   BRENDA; 3.1.4.45; 2681.
DR   UniPathway; UPA00378; -.
DR   GeneWiki; NAGPA; -.
DR   GenomeRNAi; 51172; -.
DR   PRO; PR:Q9UK23; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000103174; -.
DR   CleanEx; HS_NAGPA; -.
DR   ExpressionAtlas; Q9UK23; baseline and differential.
DR   Genevisible; Q9UK23; HS.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0003944; F:N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity; TAS:ProtInc.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:ProtInc.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0007040; P:lysosome organization; TAS:ProtInc.
DR   GO; GO:0006486; P:protein glycosylation; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006622; P:protein targeting to lysosome; TAS:ProtInc.
DR   GO; GO:0033299; P:secretion of lysosomal enzymes; IEA:Ensembl.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR018711; NAGPA.
DR   Pfam; PF09992; NAGPA; 1.
DR   PROSITE; PS00022; EGF_1; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Golgi apparatus;
KW   Hydrolase; Membrane; Polymorphism; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Zymogen.
FT   SIGNAL        1     25       {ECO:0000269|PubMed:12058031}.
FT   PROPEP       26     49       Removed in mature form.
FT                                /FTId=PRO_0000424659.
FT   CHAIN        50    515       N-acetylglucosamine-1-phosphodiester
FT                                alpha-N-acetylglucosaminidase.
FT                                /FTId=PRO_0000021788.
FT   TOPO_DOM     50    448       Lumenal. {ECO:0000255}.
FT   TRANSMEM    449    469       Helical. {ECO:0000255}.
FT   TOPO_DOM    470    515       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      358    390       EGF-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REGION      486    493       Mediates the interaction with AP4M1.
FT                                {ECO:0000269|PubMed:26544806}.
FT   MOTIF       488    491       Tyrosine-based internalization motif.
FT   MOTIF       511    515       NPF internalization motif.
FT   CARBOHYD    208    208       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    214    214       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    366    366       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    388    388       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    420    420       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    115    148       {ECO:0000305|PubMed:23572527}.
FT   DISULFID    132    323       {ECO:0000255|PROSITE-ProRule:PRU00076,
FT                                ECO:0000269|PubMed:23572527}.
FT   DISULFID    307    314       {ECO:0000305|PubMed:23572527}.
FT   DISULFID    362    373       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DISULFID    380    389       {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   VAR_SEQ     307    309       CQD -> WQA (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012267.
FT   VAR_SEQ     310    515       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012268.
FT   VAR_SEQ     392    425       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10551838}.
FT                                /FTId=VSP_012269.
FT   VARIANT      84     84       H -> Q (rare variant; found in
FT                                individuals suffering from stuttering;
FT                                unknown pathological significance;
FT                                dbSNP:rs755458782).
FT                                {ECO:0000269|PubMed:20147709}.
FT                                /FTId=VAR_073225.
FT   VARIANT     328    328       R -> C (rare variant; found in
FT                                individuals suffering from stuttering;
FT                                unknown pathological significance;
FT                                dbSNP:rs139526942).
FT                                {ECO:0000269|PubMed:20147709}.
FT                                /FTId=VAR_073226.
FT   VARIANT     465    465       T -> I (in dbSNP:rs7188856).
FT                                {ECO:0000269|PubMed:10551838}.
FT                                /FTId=VAR_020609.
FT   MUTAGEN      51     51       C->M: 65% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     115    115       C->S: 15% of wild-type of activity, and
FT                                almost no traffic to Golgi.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     132    132       C->V: No traffic to Golgi.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     137    137       N->A: 11% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     221    221       C->L: 10% of wild-type of activity; when
FT                                associated with M-51.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     225    225       Q->H: 6% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     227    227       T->R: Complete loss of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     247    247       R->A: 87% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     284    284       N->A: 22% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     286    286       D->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     287    287       G->A: 16% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     288    288       G->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     289    289       G->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     290    290       S->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     320    320       T->A: 43% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     322    322       V->A: 67% of wild-type of activity.
FT                                {ECO:0000269|PubMed:23572527}.
FT   MUTAGEN     486    486       Y->A: Interaction with AP4M1 is
FT                                abolished. {ECO:0000269|PubMed:26544806}.
FT   MUTAGEN     488    488       Y->A: Interaction with AP4M1 is
FT                                abolished. {ECO:0000269|PubMed:26544806}.
FT   MUTAGEN     491    491       L->A: Interaction with AP4M1 is
FT                                abolished. {ECO:0000269|PubMed:26544806}.
FT   CONFLICT    259    259       Q -> H (in Ref. 1; AAF08273).
FT                                {ECO:0000305}.
FT   CONFLICT    405    405       P -> R (in Ref. 1; AAF08273).
FT                                {ECO:0000305}.
SQ   SEQUENCE   515 AA;  56073 MW;  9B80335E7F9DBAA9 CRC64;
     MATSTGRWLL LRLALFGFLW EASGGLDSGA SRDDDLLLPY PRARARLPRD CTRVRAGNRE
     HESWPPPPAT PGAGGLAVRT FVSHFRDRAV AGHLTRAVEP LRTFSVLEPG GPGGCAARRR
     ATVEETARAA DCRVAQNGGF FRMNSGECLG NVVSDERRVS SSGGLQNAQF GIRRDGTLVT
     GYLSEEEVLD TENPFVQLLS GVVWLIRNGS IYINESQATE CDETQETGSF SKFVNVISAR
     TAIGHDRKGQ LVLFHADGQT EQRGINLWEM AEFLLKQDVV NAINLDGGGS ATFVLNGTLA
     SYPSDHCQDN MWRCPRQVST VVCVHEPRCQ PPDCHGHGTC VDGHCQCTGH FWRGPGCDEL
     DCGPSNCSQH GLCTETGCRC DAGWTGSNCS EECPLGWHGP GCQRPCKCEH HCPCDPKTGN
     CSVSRVKQCL QPPEATLRAG ELSFFTRTAW LALTLALAFL LLISTAANLS LLLSRAERNR
     RLHGDYAYHP LQEMNGEPLA AEKEQPGGAH NPFKD
//
